Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: A novel analgesic and neuroprotective strategy?
Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: A novel analgesic and neuroprotective strategy?
复制标题
DOI：
10.1016/j.mehy.2009.01.052
复制
发表时间：
2009-08-01
影响因子：
4.7
通讯作者：
Sarantopoulos, Constantine D.
中科院分区：
文献类型：
--
作者：
Recla, Jill M.;Sarantopoulos, Constantine D.
纤维肌痛综合征（FMS）是一种慢性广泛性疼痛综合征，估计影响4-8百万美国成年人。这种疾病的确切分子机制尚不清楚，使得大多数临床治疗和管理技术相对无效。现在已知，伤害性和中枢疼痛处理系统的异常对于FMS的发作和维持是必要的（但可能不是充分的）。这些相同的全身异常被认为是迄今为止在所有研究的FMS患者组中观察到的头部灰质密度损失的原因。目前FMS治疗的范围主要集中在镇痛，并没有明确解决潜在的神经保护策略。本文提出了一种联合治疗普瑞巴林和美金刚胺，以减少疼痛和灰质萎缩率与FMS。这种双药疗法分别靶向电压门控钙离子通道（VGCC）和N-甲基D-天冬氨酸受体（NMDAR），这是人类伤害感受和疼痛处理系统的两个主要组成部分。爱思唯尔有限公司出版
Fibromyalgia syndrome (FMS) is a chronic widespread pain syndrome that is estimated to affect 4-8 million US adults. The exact molecular mechanisms underlying this illness remain unclear, rendering most clinical treatment and management techniques relatively ineffective. It is now known that abnormalities in both nociceptive and central pain processing systems are necessary (but perhaps not sufficient) to condition the onset and maintenance of FMS. These same systemic abnormalities are thought to be responsible for the loss of cephalic gray matter density observed in all FMS patients groups studied to date. The current scope of FMS treatment focuses largely on analgesia and does not clearly address potential neuroprotective strategies. This article proposes a combined treatment of pregabalin and memantine to decrease the pain and rate of gray matter atrophy associated with FMS. This dual-drug therapy targets the voltage-gated calcium ion channel (VGCC) and the N-methyl D-aspartate receptor (NMDAR) (respectively), two primary components of the human nociceptive and pain processing systems. Published by Elsevier Ltd.